GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and ...

GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - ...

Researchers at Washington University School of Medicine in St. Louis have uncovered why some patients with a rare genetic ...

Normal lung tissue is shown on the left. On the right is lung tissue from a person with primary ciliary dyskinesia with a ...

Polish drugmaker Celon Pharma (WSE: CLN) has announced positive results from a Phase II trial of CPL’36, an experimental oral ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

Noida: A native of Kazakhstan, who had been experiencing locomotor disability for the last 14 years, as a side effect of ...

USA: A recent study has shed light on the progression of otologic and nasal symptoms in children with primary ciliary ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

Tardive dyskinesia places high physical, social, and psychological burdens on patients and their caregivers. A new online survey of U.S. caregivers spotlights their struggles. Share on Facebook.